A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

Roberto Pili, Rui Qin, P. J. Flynn, Joel Picus, Michael Millward, Wing Ming Ho, Henry Pitot, Winston Tan, Kiersten M. Miles, Charles Erlichman, Ulka Vaishampayan

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background Vascular endothelial growth factor (VEGF) is produced by bladder cancer cell lines in vitro and expressed in human bladder tumor tissues. Pazopanib is a vascular endothelial receptor tyrosine kinase inhibitor with anti-angiogenesis and anti-tumor activity in several preclinical models. A 2-stage phase II study was conducted to assess the activity and toxicity profile of pazopanib in patients with metastatic, urothelial carcinoma. Methods Patients with one prior systemic therapy for metastatic urothelial carcinoma were eligible. Patients received pazopanib at a dose of 800 mg orally for a 4-week cycle. Results Nineteen patients were enrolled. No grade 4 or 5 events were experienced. Nine patients experienced 11 grade 3 adverse events. Most common toxicities were anemia, thrombocytopenia, leucopenia, and fatigue. For stage I, none of the first 16 evaluable patients were deemed a success (complete response or partial response) by the Response Evaluation Criteria In Solid Tumors criteria during the first four 4-week cycles of treatment. Median progression-free survival was 1.9 months. This met the futility stopping rule of interim analysis, and therefore the trial was recommended to be permanently closed. Conclusions Pazopanib did not show significant activity in patients with urothelial carcinoma. The role of anti-VEGF therapies in urothelial carcinoma may need further evaluation in rational combination strategies.

Original languageEnglish (US)
Pages (from-to)477-483
Number of pages7
JournalClinical Genitourinary Cancer
Volume11
Issue number4
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Safety
Neoplasms
Carcinoma
Urinary Bladder Neoplasms
Vascular Endothelial Growth Factor A
Medical Futility
Leukopenia
Receptor Protein-Tyrosine Kinases
pazopanib
Thrombocytopenia
Disease-Free Survival
Fatigue
Blood Vessels
Anemia
Therapeutics
Cell Line

Keywords

  • Pazopanib
  • Urothelial cancer
  • VEGF tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. / Pili, Roberto; Qin, Rui; Flynn, P. J.; Picus, Joel; Millward, Michael; Ho, Wing Ming; Pitot, Henry; Tan, Winston; Miles, Kiersten M.; Erlichman, Charles; Vaishampayan, Ulka.

In: Clinical Genitourinary Cancer, Vol. 11, No. 4, 12.2013, p. 477-483.

Research output: Contribution to journalArticle

Pili, Roberto ; Qin, Rui ; Flynn, P. J. ; Picus, Joel ; Millward, Michael ; Ho, Wing Ming ; Pitot, Henry ; Tan, Winston ; Miles, Kiersten M. ; Erlichman, Charles ; Vaishampayan, Ulka. / A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. In: Clinical Genitourinary Cancer. 2013 ; Vol. 11, No. 4. pp. 477-483.
@article{a59f4836e1d34f06b11fe76ad9d8155a,
title = "A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer",
abstract = "Background Vascular endothelial growth factor (VEGF) is produced by bladder cancer cell lines in vitro and expressed in human bladder tumor tissues. Pazopanib is a vascular endothelial receptor tyrosine kinase inhibitor with anti-angiogenesis and anti-tumor activity in several preclinical models. A 2-stage phase II study was conducted to assess the activity and toxicity profile of pazopanib in patients with metastatic, urothelial carcinoma. Methods Patients with one prior systemic therapy for metastatic urothelial carcinoma were eligible. Patients received pazopanib at a dose of 800 mg orally for a 4-week cycle. Results Nineteen patients were enrolled. No grade 4 or 5 events were experienced. Nine patients experienced 11 grade 3 adverse events. Most common toxicities were anemia, thrombocytopenia, leucopenia, and fatigue. For stage I, none of the first 16 evaluable patients were deemed a success (complete response or partial response) by the Response Evaluation Criteria In Solid Tumors criteria during the first four 4-week cycles of treatment. Median progression-free survival was 1.9 months. This met the futility stopping rule of interim analysis, and therefore the trial was recommended to be permanently closed. Conclusions Pazopanib did not show significant activity in patients with urothelial carcinoma. The role of anti-VEGF therapies in urothelial carcinoma may need further evaluation in rational combination strategies.",
keywords = "Pazopanib, Urothelial cancer, VEGF tyrosine kinase inhibitors",
author = "Roberto Pili and Rui Qin and Flynn, {P. J.} and Joel Picus and Michael Millward and Ho, {Wing Ming} and Henry Pitot and Winston Tan and Miles, {Kiersten M.} and Charles Erlichman and Ulka Vaishampayan",
year = "2013",
month = "12",
doi = "10.1016/j.clgc.2013.05.005",
language = "English (US)",
volume = "11",
pages = "477--483",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

AU - Pili, Roberto

AU - Qin, Rui

AU - Flynn, P. J.

AU - Picus, Joel

AU - Millward, Michael

AU - Ho, Wing Ming

AU - Pitot, Henry

AU - Tan, Winston

AU - Miles, Kiersten M.

AU - Erlichman, Charles

AU - Vaishampayan, Ulka

PY - 2013/12

Y1 - 2013/12

N2 - Background Vascular endothelial growth factor (VEGF) is produced by bladder cancer cell lines in vitro and expressed in human bladder tumor tissues. Pazopanib is a vascular endothelial receptor tyrosine kinase inhibitor with anti-angiogenesis and anti-tumor activity in several preclinical models. A 2-stage phase II study was conducted to assess the activity and toxicity profile of pazopanib in patients with metastatic, urothelial carcinoma. Methods Patients with one prior systemic therapy for metastatic urothelial carcinoma were eligible. Patients received pazopanib at a dose of 800 mg orally for a 4-week cycle. Results Nineteen patients were enrolled. No grade 4 or 5 events were experienced. Nine patients experienced 11 grade 3 adverse events. Most common toxicities were anemia, thrombocytopenia, leucopenia, and fatigue. For stage I, none of the first 16 evaluable patients were deemed a success (complete response or partial response) by the Response Evaluation Criteria In Solid Tumors criteria during the first four 4-week cycles of treatment. Median progression-free survival was 1.9 months. This met the futility stopping rule of interim analysis, and therefore the trial was recommended to be permanently closed. Conclusions Pazopanib did not show significant activity in patients with urothelial carcinoma. The role of anti-VEGF therapies in urothelial carcinoma may need further evaluation in rational combination strategies.

AB - Background Vascular endothelial growth factor (VEGF) is produced by bladder cancer cell lines in vitro and expressed in human bladder tumor tissues. Pazopanib is a vascular endothelial receptor tyrosine kinase inhibitor with anti-angiogenesis and anti-tumor activity in several preclinical models. A 2-stage phase II study was conducted to assess the activity and toxicity profile of pazopanib in patients with metastatic, urothelial carcinoma. Methods Patients with one prior systemic therapy for metastatic urothelial carcinoma were eligible. Patients received pazopanib at a dose of 800 mg orally for a 4-week cycle. Results Nineteen patients were enrolled. No grade 4 or 5 events were experienced. Nine patients experienced 11 grade 3 adverse events. Most common toxicities were anemia, thrombocytopenia, leucopenia, and fatigue. For stage I, none of the first 16 evaluable patients were deemed a success (complete response or partial response) by the Response Evaluation Criteria In Solid Tumors criteria during the first four 4-week cycles of treatment. Median progression-free survival was 1.9 months. This met the futility stopping rule of interim analysis, and therefore the trial was recommended to be permanently closed. Conclusions Pazopanib did not show significant activity in patients with urothelial carcinoma. The role of anti-VEGF therapies in urothelial carcinoma may need further evaluation in rational combination strategies.

KW - Pazopanib

KW - Urothelial cancer

KW - VEGF tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84887993264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887993264&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2013.05.005

DO - 10.1016/j.clgc.2013.05.005

M3 - Article

VL - 11

SP - 477

EP - 483

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -